Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

verely affected HAE patients. It is also beneficial that this C1-inhibitor therapy is also to be approved for therapy of acute attacks and pre-procedure prevention."

"This positive CHMP opinion marks a key step in making Cinryze available to HAE patients across Europe and beyond that choose to proactively address their disease," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe.  "We estimate that there are several thousand patients throughout Europe who suffer from this debilitating disease, and with this recommendation, these patients may soon benefit from the unique use of Cinryze to either prevent their attacks or treat them when they occur, with the added convenience of self administration after appropriate training.  ViroPharma is committed to providing important medicines to patients with unmet medical needs, and we look forward to working closely with physicians across Europe toward this important goal."

The CHMP is the scientific advisory body of the EMA responsible for reviewing Marketing Authorization Applications for medicinal products for human use.  The CHMP positive opinion forms the scientific basis for the European Commission to issue a binding decision for a Centralized Marketing Authorization, once issued, is valid throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein. The anticipated timeframe for the European Commission decision is in the second quarter of 2011.  A summary of the CHMP opinion will be available here: http://tinyurl.com/2am4ubc.  Please select "C" to access the Cinryze summary opinion.

Continued Darcis, "Our work is already well underway towards preparing for our commercial launch in Europe, with the goal of making this important therapeutic product available to European patients as soon as possible."

Cinryze w
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... Services Outside of Houston PHOENIX, May 6 ... M. D. Anderson Cancer Center announced they will create the ... Arizona,s leading provider of health care and the nation,s leading ... unprecedented level of cancer care in Arizona.Located at US 60 ...
... May 6 The healthcare industry in ... inequalities in access to care. The public ... of the population, yet accounts for around ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )Public-private partnerships offer an innovative means ...
... wife Ellen honored for generous contribution to New York University College ... ... Dr. Jan Linhart, D.D.S. and his wife, Ellen Linhart, have established ... Program at Dr. Linhart’s alma mater. In honor of this act ...
... with a humanitarian award at a glittering ceremony in London last night. ... ... of the world,s largest hospital ship charity were honored with a humanitarian ... , , ,The annual Variety Club International Humanitarian Award , whose ...
... Max Muscle Sports Nutrition,s newest product innovation is L-Tox, for advanced ... along with protective and regenerative factors. , ... Anaheim, ... Administration (FDA) www.fda.gov issued a stop product use directive ...
... small non-profit Ohio Biotech firm, has confirmed that they have decoded ... currently reported Swine Flu outbreak. , ... Albany, Ohio ... of infection and the first reported American death from the new ...
Cached Medicine News:Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 2Health News:Banner Health, M. D. Anderson Announce Cancer Care Facility for Arizona 3Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 2Health News:South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan 3Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 2Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 3Health News:Mercy Ships Founders Receive Humanitarian of the Year Award From Variety Club 4Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 2Health News:Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall 3Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 2Health News:BioTech Firm Decodes Current Swine Flu BioMarkers 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: